Assessing And Navigating Testing For Parenteral Packaging And Delivery Systems: Container Closure Integrity
By Jennifer Riter

Container Closure Integrity (CCI) is a key area that needs to be evaluated in the development phase of drug products. CCI is defined as the ability of a package to prevent product loss, to block the ingress of microorganisms, and to limit entry of detrimental gases or other substances over the shelf life – ensuring that the drug product meets all necessary safety and quality standards. This article discusses the chapters in USP <1207> Package Integrity Evaluation – Sterile Products, which covers CCI and different methods of selection and validation.
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
West Pharmaceutical Services, Inc.
This website uses cookies to ensure you get the best experience on our website. Learn more